Azenta Inc (AZTA)vsJohnson & Johnson (JNJ)
AZTA
Azenta Inc
$39.16
+4.76%
HEALTHCARE · Cap: $1.81B
JNJ
Johnson & Johnson
$276.22
+1.43%
HEALTHCARE · Cap: $657.68B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 16083% more annual revenue ($99.33B vs $613.81M). JNJ leads profitability with a 16.2% profit margin vs -20.0%. AZTA appears more attractively valued with a PEG of 0.53. AZTA earns a higher WallStSmart Score of 55/100 (C-).
AZTA
Buy55
out of 100
Grade: C-
JNJ
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+34.6%
Fair Value
$46.55
Current Price
$39.16
$7.39 discount
Intrinsic value data unavailable for JNJ.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Earnings expanding 8778.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Mega-cap, among the largest globally
Strong operational efficiency at 25.7%
Generating 6.4B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
ROE of -11.5% — below average capital efficiency
Negative free cash flow — burning cash
Currently unprofitable
Trading at 8.2x book value
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : AZTA
The strongest argument for AZTA centers on Price/Book, EPS Growth, Debt/Equity. Revenue growth of 12.0% demonstrates continued momentum. PEG of 0.53 suggests the stock is reasonably priced for its growth.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.7%.
Bear Case : AZTA
The primary concerns for AZTA are Market Cap, Return on Equity, Free Cash Flow.
Bear Case : JNJ
The primary concerns for JNJ are Price/Book, Piotroski F-Score, PEG Ratio. A P/E of 41.5x leaves little room for execution misses.
Key Dynamics to Monitor
AZTA profiles as a turnaround stock while JNJ is a mature play — different risk/reward profiles.
AZTA carries more volatility with a beta of 1.52 — expect wider price swings.
AZTA is growing revenue faster at 12.0% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
AZTA scores higher overall (55/100 vs 54/100) and 12.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Azenta Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Azenta Inc. is a premier provider of sample management solutions and life science tools, dedicated to enhancing laboratory efficiencies within the biotechnology and pharmaceutical industries. The company excels in innovative automation and comprehensive biorepository services, facilitating faster drug discovery while ensuring adherence to stringent regulatory standards. With a forward-looking strategy that leverages advanced storage technologies and strategic partnerships, Azenta is uniquely positioned to seize growth opportunities in the expanding global life sciences market. Its commitment to pioneering scientific research through sophisticated innovations underscores its potential appeal to institutional investors seeking exposure in the dynamic life sciences sector.
Visit Website →Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?